mFlusiva flu shot concerns

A newly approved flu vaccine using mRNA technology, called mFlusiva, has received FDA approval for individuals aged 50 and older. Studies indicate it is more effective than traditional flu vaccines, with potential to improve matching circulating strains and reduce flu-related deaths. However, public skepticism about mRNA vaccines persists, potentially hindering widespread adoption.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل